Chronic Kidney Disease, Hypertension
Conditions
Keywords
sympatholytic treatment, sympathetic nerve activity
Brief summary
The primary purpose is to assess the role of sympathetic activation for the development and progression of chronic renal failure. Using microneurography sympathetic activity will be registered in various stages of kidney affection or failure and hypertension. A sympatholytic agent will be compared with a non-sympatholytic drug to asses the effect sympathetic activation and on the progression of kidney disease. The effects of a sympatholytic agent on cardiovascular reactivity to various stressors wil be examined.
Interventions
DRUGRilmenidine
1 mg Rilmenidine per day versus
DRUGNitrendipine
20 mg Nitrendipine per day
Sponsors
University of Erlangen-Nürnberg Medical School
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* chronic renal failure stages I-IV
Exclusion criteria
* pregnancy and lactation * severe heart failure or ischemic heart disease * patients with NYHA III-IV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sympathetic activation for the development and progression of chronic renal failure | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| effects of a sympatholytic agent on cardiovascular reactivity to various stressors | 3 months |
Countries
Germany
Outcome results
None listed